A new prognostic classification after primary chemotherapy for breast cancer: Residual disease in breast and nodes (RDBN)

Cancer Journal

Volumn 14, Issue 2, 2008, Pages 128-132

  Chollet, Philippe ^a,b,c,d   Abrial, Catherine ^a   Durando, Xavier ^a,c   Thivat, Emilie ^a   Tacca, Olivier ^a   Mouret Reynier, Marie Ange ^a,c   Leheurteur, Marianne ^a,c   Kwiatkowski, Fabrice ^a   Dauplat, Jacques ^a,c   Penault Llorc, Frédérique ^a,b,c  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Centre DInvestigation Clinique   (France)

Author keywords

Breast cancer; Pathologic classification; Residual disease

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUMOR VOLUME; BREAST TUMOR; CLASSIFICATION; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 50949115630     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31816bdea2     Document Type: Article

References (30)

1. Cure H, Amat S, Penault-Llorca F, et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat. 2002;76:37-45.
2. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86:1041-1046.
3. Amat S, Penault-Llorca F, Cure H, et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol. 2002;20:791-796.
4. Adjuvant Therapy for Breast Cancer. NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 2000;17(No. 4):1-35.
5. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502-509.
6. Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg. 2003;237:732-739.
7. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16(1):93-100.
8. Brain E, Garrino C, Misset JL, et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer. 1997;75: 1360-1367.
9. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
10. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207-219.
11. Chollet P, Amat S, Belembaogo E, et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer. 2003;6:89:1185-1191.
12. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer. 1982;45:361-366.
13. Baslev I, Axelsson CK, Zedeler K, et al. The Nottingham prognostic index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat. 1994;32: 281-290.
14. Belembaogo E, Feillel V, Chollet P, et al. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer. 1992;28A:896-900.
15. Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer. 1997;33:862-866.
16. Chollet P, Amat S, Penault-Llorca F, et al. High pathological response rate induced by primary docetaxel monotherapy in operable breast cancer (Meeting abstract). Breast Cancer Res Treat. 2000;64:A251.
17. Van Praagh I, Amat S, Delva R, et al. Induction chemotherapy in operable breast cancer by NET regimen: multicentric phase II trial (Meeting abstract). J Clin Oncol. 2001;18:A1889.
18. Van Praagh I, Cure H, Leduc B, et al. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist. 2002;7:418-423.
19. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88:1339-1345.
20. Abrial C, Van Praagh I, Delva R, et al. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist. 2001;10:242-249.
21. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1957;53:457-471.
22. Chollet P, Curé H, Amat S, et al. A new prognostic classification after primary chemotherapy (PC) for breast cancer (BC). Am Assoc Cancer Res. 2005;108:LB-215.
23. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer: pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223-228.
24. Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg. 1998;175:127-132.
25. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578-2581.
26. Viens P, Penault-Llorca F, Jacquemier J, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant. 1998;21:249-254.
27. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998;77:621-626.
28. Costa SD, von Minckwitz G, Raab G, et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 1999;26(suppl 9):24-31.
29. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180:297-306.
30. Symmans WF, Peintiger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-4422.